IPSC at a glance
The past year
Chart+190.3% $1.37, close Nov 17
- From the highest close
- −53.4%
- Vs the 200-day average
- −33.5%
Short interest
History32.0M shares
- Of shares outstanding
- 17.6%
- Since the last report
- +9.9%
- Days to cover
- 31 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 12 – Nov 18
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
IPSC price history
Loading recent earnings…
Investment thesis
What must happen next
Century’s off-the-shelf pluripotent stem-cell platform remains partner-worthy because it addresses the scalability limits of autologous cell therapy; that only matters if collaboration or contract economics recur rather than appearing as a one-time accounting event.HoldingMateriality: High
GAAP annual revenue increased from $6.589 million in FY2024 to $109.164 million in FY2025. If partner demand persists, non-dilutive capital can fund the pipeline; if it fades, shareholders must finance expensive cell-therapy R&D themselves.
Watch: Existing or prospective pharmaceutical partners terminate, pause, or decline new iPSC/allogeneic cell-therapy collaborations after reviewing data.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $6.589 million in FY2024 to $109.164 million in FY2025.
Open source ↗Cash runway is the gating strategic constraint, so Century must either reduce burn, raise non-dilutive capital, or sequence programs tightly enough to avoid financing the whole platform through distressed equity.WeakeningMateriality: High
Cash and cash equivalents were $61.853 million at FY2025 year-end. The same science can be worth far less per share if it requires repeated dilutive financings before proof of concept.
Watch: Clinical trial expansion, manufacturing scale-up, or CMC remediation increases cash needs before new milestones arrive.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents were $61.853 million at FY2025 year-end.
Open source ↗Century’s lean organization must be capable of advancing complex cell-therapy development through focused execution and external leverage; if the platform requires broad internal manufacturing and clinical infrastructure, the model becomes under-resourced.HoldingMateriality: Medium
The company reported 78 full-time employees as of March 1, 2026. A small team can be efficient if the platform is modular and partnered, but it becomes a constraint if each program needs bespoke infrastructure.
Watch: Manufacturing comparability, release testing, or scale-up problems require a major internal buildout.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company reported 78 full-time employees as of March 1, 2026.
Open source ↗The path to improved economics depends on high-value collaboration or milestone revenue absorbing the fixed cost base; without repeat partner payments, operating losses will revert toward the underlying R&D burden.HoldingMateriality: Medium
GAAP annual operating loss improved to $17.269 million in FY2025 from $138.137 million in FY2024. This determines whether Century can fund value-creating development internally or remains dependent on external financing.
Watch: FY2025 revenue proves to be a non-recurring payment with no follow-on milestones or new collaborations.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss improved to $17.269 million in FY2025 from $138.137 million in FY2024.
Open source ↗A lighter liability load gives Century some negotiating flexibility, but that advantage disappears if new obligations or financing claims are added before the platform is clinically de-risked.HoldingMateriality: Medium
Total liabilities declined from $191.854 million at FY2024 year-end to $64.768 million at FY2025 year-end. Lower balance-sheet encumbrance can preserve upside for common shareholders; new senior claims can transfer future platform value away from equity.
Watch: The company takes on secured debt, royalty financing, or onerous manufacturing commitments to fund trials.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Total liabilities declined from $191.854 million at FY2024 year-end to $64.768 million at FY2025 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Century’s off-the-shelf pluripotent stem-cell platform remains partner-worthy because it addresses the scalability limits of autologous cell therapy; that only matters if collaboration or contract economics recur rather than appearing as a one-time accounting event. If partner demand persists, non-dilutive capital can fund the pipeline; if it fades, shareholders must finance expensive cell-therapy R&D themselves.
Cash runway is the gating strategic constraint, so Century must either reduce burn, raise non-dilutive capital, or sequence programs tightly enough to avoid financing the whole platform through distressed equity. The same science can be worth far less per share if it requires repeated dilutive financings before proof of concept.
Century’s lean organization must be capable of advancing complex cell-therapy development through focused execution and external leverage; if the platform requires broad internal manufacturing and clinical infrastructure, the model becomes under-resourced. A small team can be efficient if the platform is modular and partnered, but it becomes a constraint if each program needs bespoke infrastructure.
The path to improved economics depends on high-value collaboration or milestone revenue absorbing the fixed cost base; without repeat partner payments, operating losses will revert toward the underlying R&D burden. This determines whether Century can fund value-creating development internally or remains dependent on external financing.
A lighter liability load gives Century some negotiating flexibility, but that advantage disappears if new obligations or financing claims are added before the platform is clinically de-risked. Lower balance-sheet encumbrance can preserve upside for common shareholders; new senior claims can transfer future platform value away from equity.
All standing thesis claims
Original report summary
Century Therapeutics is a high-risk platform biotech whose value depends on proving that allogeneic pluripotent stem-cell therapies can become partnered, clinically validated products before cash burn forces dilution.
Bull case and bear case
Bull case and bear case for Century Therapeutics
Where the evidence on Century Therapeutics disagrees: Mixed on the latest evidence (Nov 16, 2026). Of its 5 thesis points, 4 holding and 1 weakening.
Bull case: what the evidence supports
Century’s off-the-shelf pluripotent stem-cell platform remains partner-worthy because it addresses the scalability limits of autologous cell therapy; that only matters if collaboration or contract economics recur rather than appearing as a one-time accounting event.
Century’s lean organization must be capable of advancing complex cell-therapy development through focused execution and external leverage; if the platform requires broad internal manufacturing and clinical infrastructure, the model becomes under-resourced.
The path to improved economics depends on high-value collaboration or milestone revenue absorbing the fixed cost base; without repeat partner payments, operating losses will revert toward the underlying R&D burden.
A lighter liability load gives Century some negotiating flexibility, but that advantage disappears if new obligations or financing claims are added before the platform is clinically de-risked.
Bear case: what the evidence questions
Cash runway is the gating strategic constraint, so Century must either reduce burn, raise non-dilutive capital, or sequence programs tightly enough to avoid financing the whole platform through distressed equity.
Company research
Research on Century Therapeutics
- Reporting · Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches
Five clinical-scale runs now support consistent manufacturing, up from three in June. The program still has no human safety or efficacy data.
Thesis-Break Engine
Thesis-break watch · Century Therapeutics
No break has crossed Century Therapeutics’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Century Therapeutics filed an SEC 8-K on 2026-11-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Century Therapeutics filed an SEC 8-K on 2026-10-02: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Century Therapeutics filed an SEC 8-K on 2026-09-09: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Existing or prospective pharmaceutical partners terminate, pause, or decline new iPSC/allogeneic cell-therapy collaborations after reviewing data.
- Clinical trial expansion, manufacturing scale-up, or CMC remediation increases cash needs before new milestones arrive.
- Manufacturing comparability, release testing, or scale-up problems require a major internal buildout.
- FY2025 revenue proves to be a non-recurring payment with no follow-on milestones or new collaborations.
- The company takes on secured debt, royalty financing, or onerous manufacturing commitments to fund trials.
IPSC news
Loading headlines…
Financial statements
IPSC income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
IPSC: quick answers
- When does Century Therapeutics (IPSC) report earnings next?
- Century Therapeutics's next results are projected for March 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 12, 2026. Earnings calendar
- What is IPSC's short interest?
- As of October 30, 2026, 32.0M IPSC shares were sold short, 17.6% of its shares outstanding, up 9.9% from the count before. At the stock's average daily volume that is 31 days to cover. FINRA publishes the count twice a month. IPSC short interest history

